Efficacy Of Different Chemotherapy In The Treatment Of Multiple Myeloma

Objective:The aim of this study was to evaluate the efficacy of bortezomib-basedchemotherapy and other conventional chemotherapy treatment of multiple myeloma.Materials and methods: Retrospective analysis of the62cases of multiplemyeloma patients at our hospital from March2006to May2011,among of these cases,23patients (newly diagnosed14cases,relapsed/refractory9cases) were treated withVDT regimen (bortezomib+dexamethasone+thalidomide) and39patients (newlydiagnosed33cases,relapsed/refractory6cases) were treated with other conventionalchemotherapy (such as MPT,VAD and improved M2, et al.).To compare the VDTregimen with other conventional chemotherapy of the overall efficiency and survivalrate, the efficiency of the untreated and relapsed/refractory groups, the overall completeremission rate, the complete remission rate of the untreated and relapsed/refractorygroups, and the relationship between the number of courses and the efficacy. The х2test,t test, Kaplan-Meiter method and Log-Rank test of SPSS17.0software were used forstatistical analysis.Results: The total effective rate of VDT regimen was95.7%and otherconventional chemotherapy was74.4%,and there was significant difference.In theuntreated group,the effective rate of VDT regimen was100%and other conventionalchemotherapy was78.8%,and in the relapsed/refractory group,the effective rate of VDTregimen was88.9%and other conventional chemotherapy was50%,but there was nosignificant difference in two group. The overall complete remission rate of VDTregimen was52.5%and other conventional chemotherapy was12.8%,and there wassignificant difference. In the untreated group,the complete remission rate of VDTregimen was57.1%and other conventional chemotherapy was9.1%, and there wassignificant difference. In the relapsed/refractory group,the complete remission rate ofVDT regimen was44.4%and other conventional chemotherapy was33.3%,but there was no significant difference. In the group of VDT regimen and other conventionalchemotherapy,the median number of courses with CR was3(1-6) and4（2-5),respectively,and there was no significant difference between them. The mediannumber of courses of the overall efficiency in both group was3（1-6）and4（2-7),respectively,and there was significant difference between them.Observed fromthe survival curves,the VDT regimen was better than the other conventionalchemotherapy,but neither of them had significant difference.Conclusion:Compared with other conventional treatment,the overall response rateof VDT regimen was higher, and there was significant difference.In the multiplemyeloma patients of newly diagnosed and relapsed/refractory,the response rate of theVDT regimen was better than the other conventional chemotherapy,but there was nosignificant difference between them. The overall complete remission rate and thecomplete remission rate in the untreated group of VDT regimen was higher than theother conventional chemotherapy, and there was significant difference. In therelapsed/refractory group,the complete remission rate of VDT regimen was higher thanthe other conventional chemotherapy too, but there was no significant difference. Themedian number of courses of the overall efficiency and the median number of courseswith CR in the VDT regimen was less than the other conventional treatment,but therewas significant difference in the former and no significant difference in thelatter.Observed from the survival curves,the VDT regimen was better than the otherconventional chemotherapy,but there was no significant difference.